Sanofi-aventis, Innogenetics, and Inserm to collaborate on Alzheimer's disease
Sanofi-aventis, Innogenetics, and Inserm, through its subsidiary called Inserm Transfert, announced the conclusion of a collaborative research agreement in the field of Alzheimer's disease. This collaboration agreement is signed for an initial period of 2 years, with an option for Sanofi-aventis to obtain an exclusive worldwide license on the results arising from the research program in the therapeutics field. Innogenetics will have an exclusive worldwide license in the diagnostics field.
The present agreement is built on intellectual property and a research collaboration between Innogenetics and Inserm-Lille (U-422) on the development of new diagnostic tools for Alzheimer's disease (AD) dating back from 2002. The results of the collaboration shall allow to study the role of specific forms of the key Alzheimer protein amyloid beta, and related technology, as targets for new therapeutic avenues for AD. Based on the technology and products provided by Innogenetics and Inserm, Sanofi will evaluate different products against diverse forms of the beta protein in a passive immunization program. In return for providing Sanofi-aventis access to their technology and services, Innogenetics and Inserm-Transfert will receive upfront and research fees.
In the event Sanofi-aventis exercises its license option, Innogenetics and Inserm-Transfert will be entitled to milestone payments and royalties on future sales of therapeutic products resulting from this collaboration.
Financial terms of the agreement were not disclosed.
Most read news
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Last viewed contents
Biogen Idec and Alnylam Alliance to Develop Therapeutics for Treatment of Progressive Multifocal Leukoencephalopathy (PML)
William S. Marth Appointed to AMRI's Board of Directors
Florida_Dental_Association
IXICO and PsiOxus Therapeutics win significant funding from government-backed Biomedical Catalyst
Novartis gains exclusive rights to Debio 025, an antiviral agent as potential first-in-class hepatitis C therapy - Novartis to make upfront payment to Debiopharm Group, with Debiopharm eligible for milestones and royalties on future sales
Merck & Co. Announces New Name for its Animal Health Division
PolyTherics appoints new Chairman
Germany Begins its First AIDS Vaccine Trial, Partnering with IAVI
MedImmune to Collaborate With National Institutes of Health to Develop Pandemic Influenza Vaccine
Pharmexa presents data from influenza program
Dental_public_health
